Aperture Venture Partners is a venture capital group focused primarily on the healthcare and healthy living industries. Initial investment size ranges between $1 million and $5 million and they invest nationally.
Aperture Venture Partners is a New York, New York-based healthcare-focused venture capital firm. It prefers to invest in the consumer goods, medical device, biopharmaceutical, biotechnology, healthcare information technology services and diagnostic sectors. The firm was founded in 2002 by Eric H. Sillman and Paul E. Tierney, Jr.
The firm works exclusively in the healthcare industry. Aperture's principals have been entrepreneurs in the healthcare and investment industries. They have invested more than $1 billion and founded companies that have had combined revenues greater than $2 billion.
Aperture Venture Partners has raised a total of $49.2M in a single venture fund, Aperture Venture Partners III, L.P. This fund was announced on Dec 31, 2014, and raised a total of $49.2M. The firm has made 34 investments, one of which was on Sep 14, 2018, when they invested $45M in ENDOTRONIX. Aperture Venture Partners has had 15 exits, the most notable ones including Avedro, Inspire Medical Systems, and Aclaris Therapeutics. The firm has $6.4M in revenue annually.
Aperture Venture Partners, LLC is a venture capital firm specializing in early-stage investments. It seeks to invest in the healthcare and healthy living industries. Within the healthcare industry, the firm invests in biopharmaceutical, biotechnology, healthcare services, healthcare information technology, diagnostics, drug discovery/delivery, and medical devices. Its investments in the healthy living category include companies that offer products or services in the areas of personal care; weight management; complementary and alternative medicines; vitamins, minerals, and supplements; beverages; sporting goods; apparel; retail; and travel. The firm seeks to invest in companies based in the West Coast and North Eastern United States. It typically invests between $1 million and $5 million in its portfolio companies. The firm seeks to be the lead investor and can also co-invest.
Series D - ENDOTRONIX
Series C - V-Wave
Series B - Cardiac Dimensions
Series C - ENDOTRONIX
Series C - Channel Medsystems
Series A - Neuros Medical
Series C - Trevi Therapeutics
Venture Round - Biohaven Pharmaceutical
Series C - Spirox
Series C - Aclaris Therapeutics
Aperture Venture Partners III, L.P.
Eric H. Sillman
Paul E. Tierney, Jr.
Co-Founder, Managing Member, Managing Partner and General Partner
Thomas P. Cooper
Aperture Venture Partners - The Friar Files
Aperture Venture Partners Archives - MassDevice
Aperture Venture Partners Raising $100M Fund
Wall Street Journal
Avedro Completes $25 Million Series C Financing SCP Vitalife and Aperture Venture Partners join existing investors
Eric Sillman - Aperture Venture Partners General Partner | Signal
Neuros Medical Closed $20M in Venture Capital Financing |FinSMEs
V-Wave Closes $70M Financing to Support Pivotal Study of its Heart Failure Therapy
Documentaries, videos and podcasts
Eric Silman discusses impact investing and the role of accelerators in building the field.
Jul 31, 2012
How to Source Deals: 2nd Annual PE/VC Conference
Jul 24, 2018
Inverted Approach for Capturing Alpha: 2nd Annual PE/VC Conference
Jul 24, 2018
Private Equity in Emerging Markets: Looking Beyond the Internal Rate of Return
November 9, 2010
Sector Specific Due Diligence: 2nd Annual PE/VC Conference
Tony Natale, MD, Aperture Venture Partners, Intro: 2nd Annual PE/VC Conference
Jul 24, 2018